中国实用儿科杂志2025，Vol.40Issue(8)：645-651,7.DOI:10.19538/j.ek2025080603
2024年版《关于川崎病诊断与管理的最新进展:美国心脏协会科学声明》解读
Interpretation of the 2024 edition of Update on Diagnosis and Management of Kawasaki Disease:A Scientific Statement From the American Heart Association
鞠晨晖 1肖燕燕 1高路 1金红芳2
作者信息
- 1. 国家儿童医学中心首都医科大学附属北京儿童医院心脏内科,北京 100045
- 2. 北京大学第一医院儿科,北京 100034
- 折叠
摘要
Abstract
Kawasaki disease(KD)is an acute self-limiting febrile disorder that mainly affects children under 5 years old.The 2024 edition of"Update on Diagnosis and Management of Kawasaki Disease:A Scientific Statement From the American Heart Association"updates and summarizes the clinical research progress related to diagnosis,acute-phase cardiac imaging examinations,and long-term management since the American Heart Association released the KD scientific statement in 2017.The new statement updates the diagnostic criteria for patients at high risk of coronary artery aneurysms in the North American population,who may benefit from more aggressive initial treatment.Advances in cardiovascular imaging technology have enhanced our ability to identify coronary artery stenosis in KD patients.The latest research on KD treatment has deepened our understanding of the safety and dosage regimens of multiple anti-inflammatory treatments for KD.The new statement also explores key clinical issues such as the application of new oral anticoagulants,management plans for myocardial infarction,selection of anti-platelet drugs,anti-coagulation treatment strategies,and methods for assessing myocardial ischemia,with particular emphasis on long-term follow-up management strategies for patients with coronary artery complications.关键词
川崎病/诊断/治疗/管理Key words
Kawasaki disease/diagnosis/treatment/management分类
医药卫生引用本文复制引用
鞠晨晖,肖燕燕,高路,金红芳..2024年版《关于川崎病诊断与管理的最新进展:美国心脏协会科学声明》解读[J].中国实用儿科杂志,2025,40(8):645-651,7.
